Drug Profile

Research programme: small-molecule therapeutics - Elicio Therapeutics

Alternative Names: ANG 3586; ANG-3067; ANG-3281; ANG-3407; ANG-4011; ANG-4021

Latest Information Update: 07 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Angion Biomedica
Developer Elicio Therapeutics
Class Antifibrotics; Antineoplastics; Small molecules
Mechanism of Action Peptide hormone stimulants; Retinoic acid receptor modulators; Retinoid X receptor modulators; Steroid 17-alpha-hydroxylase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Jun 2023 Angion Biomedica has merged with Elicio Therapeutics to form Elicio Therapeutics
01 Aug 2019 Discontinued - Preclinical for Kidney disorders in USA (unspecified route)
01 Aug 2019 Discontinued for Fibrosis in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com